Positive News SentimentPositive NewsNASDAQ:EOLS Evolus (EOLS) Stock Price, News & Analysis $10.84 -0.05 (-0.46%) (As of 05:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Evolus Stock (NASDAQ:EOLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evolus alerts:Sign Up Key Stats Today's Range$10.63▼$11.0050-Day Range$10.84▼$17.4552-Week Range$9.80▼$17.82Volume551,573 shsAverage Volume590,379 shsMarket Capitalization$686.40 millionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingBuy Company OverviewEvolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Read More… Evolus Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks79th Percentile Overall ScoreEOLS MarketRank™: Evolus scored higher than 79% of companies evaluated by MarketBeat, and ranked 217th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvolus has only been the subject of 1 research reports in the past 90 days.Read more about Evolus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.63) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -11.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -11.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.23% of the outstanding shares of Evolus have been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Evolus has recently decreased by 1.51%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Sustainability and ESG3.5 / 5Environmental Score-1.27 Percentage of Shares Shorted8.23% of the outstanding shares of Evolus have been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Evolus has recently decreased by 1.51%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News SentimentN/A News SentimentEvolus has a news sentiment score of 1.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.10% of the stock of Evolus is held by insiders.Percentage Held by Institutions90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Evolus' insider trading history. Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address EOLS Stock News HeadlinesEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 13, 2024 | businesswire.comEvolus’ Resilience and Growth Potential Amid Market Challenges: A Buy Recommendation by Uy EarNovember 20, 2024 | markets.businessinsider.com70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.December 23, 2024 | WealthPress (Ad)Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their ForecastsNovember 9, 2024 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comEvolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market ChallengesNovember 7, 2024 | finance.yahoo.comEvolus Maintains Strong Growth Outlook Despite Earnings Miss: A Buy RecommendationNovember 7, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Evolus (EOLS)November 7, 2024 | markets.businessinsider.comSee More Headlines EOLS Stock Analysis - Frequently Asked Questions How have EOLS shares performed this year? Evolus' stock was trading at $10.53 on January 1st, 2024. Since then, EOLS shares have increased by 2.9% and is now trading at $10.84. View the best growth stocks for 2024 here. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) issued its earnings results on Tuesday, March, 23rd. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.18. The firm earned $20.58 million during the quarter, compared to analyst estimates of $20.60 million. Evolus had a negative net margin of 22.33% and a negative trailing twelve-month return on equity of 847.60%. Read the conference call transcript. When did Evolus IPO? Evolus (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. Who are Evolus' major shareholders? Evolus' top institutional investors include Caligan Partners LP (3.46%), Stonepine Capital Management LLC (2.16%), State Street Corp (2.02%) and Geode Capital Management LLC (1.91%). Insiders that own company stock include Alphaeon 1 Llc, Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Lauren P Silvernail, Tomoko Yamagishi-Dressler, David N Gill, Robert Hayman and Crystal Muilenburg. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings3/23/2021Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EOLS CUSIPN/A CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$27.00 Low Stock Price Target$20.00 Potential Upside/Downside+112.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,690,000.00 Net Margins-22.33% Pretax Margin-22.20% Return on Equity-847.60% Return on Assets-22.15% Debt Debt-to-Equity Ratio20.58 Current Ratio2.47 Quick Ratio2.23 Sales & Book Value Annual Sales$248.33 million Price / Sales2.76 Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-30.11Miscellaneous Outstanding Shares63,321,000Free Float59,458,000Market Cap$686.40 million OptionableOptionable Beta1.27 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:EOLS) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.